DE60112917D1 - Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität - Google Patents

Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität

Info

Publication number
DE60112917D1
DE60112917D1 DE60112917T DE60112917T DE60112917D1 DE 60112917 D1 DE60112917 D1 DE 60112917D1 DE 60112917 T DE60112917 T DE 60112917T DE 60112917 T DE60112917 T DE 60112917T DE 60112917 D1 DE60112917 D1 DE 60112917D1
Authority
DE
Germany
Prior art keywords
alpha2 adrenergic
adrenergic activity
new polycyclic
indanylimidazole
polycyclic indanylimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60112917T
Other languages
English (en)
Other versions
DE60112917T2 (de
Inventor
Jari Ratilainen
Paavo Huhtala
Arto Karjalainen
Arja Karjalainen
Antti Haapalinna
Raimo Virtanen
Jyrki Lehtimaeki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of DE60112917D1 publication Critical patent/DE60112917D1/de
Application granted granted Critical
Publication of DE60112917T2 publication Critical patent/DE60112917T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60112917T 2000-05-08 2001-05-07 Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität Expired - Fee Related DE60112917T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20001065 2000-05-08
FI20001065 2000-05-08
PCT/FI2001/000434 WO2001085698A1 (en) 2000-05-08 2001-05-07 New polycyclic indanylimidazoles with alpha2 adrenergic activity

Publications (2)

Publication Number Publication Date
DE60112917D1 true DE60112917D1 (de) 2005-09-29
DE60112917T2 DE60112917T2 (de) 2006-06-08

Family

ID=8558343

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112917T Expired - Fee Related DE60112917T2 (de) 2000-05-08 2001-05-07 Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität

Country Status (16)

Country Link
US (1) US6362211B2 (de)
EP (1) EP1280779B1 (de)
JP (1) JP2003532712A (de)
AT (1) ATE302757T1 (de)
AU (2) AU2001258469B2 (de)
CA (1) CA2408290A1 (de)
CZ (1) CZ20023674A3 (de)
DE (1) DE60112917T2 (de)
ES (1) ES2247107T3 (de)
IL (1) IL152401A0 (de)
NO (1) NO20025323D0 (de)
NZ (1) NZ522274A (de)
PE (1) PE20011321A1 (de)
PT (1) PT1280779E (de)
RU (1) RU2002132883A (de)
WO (1) WO2001085698A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835834B1 (fr) * 2002-02-14 2004-04-02 Pf Medicament Nouveaux derives de tricyclo-imidazolines, leur procede de preparation et leur utilisation a titre de medicaments
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
US8188126B2 (en) * 2002-05-16 2012-05-29 Pierre Fabre Medicament Imidazolic compounds and use thereof as alpha-2 adrenergic receptors
US20110190247A1 (en) * 2008-08-04 2011-08-04 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
US10826751B2 (en) * 2009-12-28 2020-11-03 Telefonaktiebolaget Lm Ericsson (Publ) Management of functional interconnections between application modules on resource nodes in a social web
JP7254036B2 (ja) * 2017-06-26 2023-04-07 バイオ―ラッド ヨーロッパ ゲーエムベーハー その場段階希釈法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
GB2225782A (en) 1988-12-09 1990-06-13 Farmos Group Limited Imidazole derivatives useful for treatment of diabetes
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives

Also Published As

Publication number Publication date
US20020013356A1 (en) 2002-01-31
AU2001258469B2 (en) 2005-04-14
PT1280779E (pt) 2005-11-30
EP1280779B1 (de) 2005-08-24
US6362211B2 (en) 2002-03-26
CA2408290A1 (en) 2001-11-15
JP2003532712A (ja) 2003-11-05
IL152401A0 (en) 2003-05-29
NO20025323L (no) 2002-11-06
WO2001085698A1 (en) 2001-11-15
NZ522274A (en) 2004-11-26
PE20011321A1 (es) 2002-01-03
ATE302757T1 (de) 2005-09-15
RU2002132883A (ru) 2004-04-20
DE60112917T2 (de) 2006-06-08
ES2247107T3 (es) 2006-03-01
AU5846901A (en) 2001-11-20
CZ20023674A3 (cs) 2003-09-17
EP1280779A1 (de) 2003-02-05
NO20025323D0 (no) 2002-11-06

Similar Documents

Publication Publication Date Title
MX9800867A (es) Halogenobencimidazoles y su empleo como microbicidas.
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
ATE270817T1 (de) Fungizide
ATE233274T1 (de) Oxyiminopregnancarbolactone
DE69834508D1 (de) Aptoptoseinhibitoren
TR200402069T4 (tr) Difenilüre türevleri ve bunların alfa 2/5-HT2c antagonisti olarak kullanılması
DE60012809D1 (de) 2-Pyridinylguanidine als Urokinase Inhibitoren
DE60316672D1 (de) Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten
EA199900935A1 (ru) Соединения индазоламида в качестве серотонинергических агентов
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
ATE359073T1 (de) Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel
DE69821530D1 (de) Dihydrobenzifurane
ATE302772T1 (de) 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
PT1301503E (pt) Derivados da cumarina com actividade inibidora de comt
PT1242410E (pt) Compostos novos
DE60112917D1 (de) Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität
SE9903290D0 (sv) Novel compounds
ATE273985T1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
DE60017374D1 (de) Antibakterielle mittel
DE69615657D1 (de) Antifungal fusacandine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee